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ABSTRACT
Chronic illness in pregnant women is common. In epilepsy, bipolar disorder (BD) or major 
depressive disorder (MDD), pharmacotherapy is often necessary. Some neurotropic drugs 
may have negative effects on children exposed in utero. The aim of this thesis was to describe 
how neurotropic drugs and/or maternal chronic illness during pregnancy may influence the 
health of the child, both in the neonatal period and long-term outcome, with emphasis on 
neurodevelopment. In study I, we investigated school results at age 16 in children born to 
women with epilepsy (WWE), with or without antiepileptic drugs (AED) during pregnancy. 
Study II and study III aimed at describing neonatal morbidity in infants prenatally exposed 
to antidepressant drugs. In study IV we studied neonatal and long-term outcome of children 
born to mothers with severe mood disorders, mostly BD.
Methods: In study I, national health care and education registers as well as maternal care 
records were used to compare final grades of children of WWE with the rest of the popula-
tion. Study II was a retrospective, hospital-based study of patient records of women treated 
with antidepressants in late pregnancy and their children. Information on neonatal diagnoses, 
maternal use of antidepressant drugs and scoring according to Neonatal Abstinence Score 
(NAS) was used. In study III, we used the Medical Birth Register, the Prescribed Drug Re-
gister and two neonatal quality registers to obtain data on maternal use of antidepressants, 
maternal health and infant morbidity (diagnoses, admission to neonatal care unit (NCU) and 
interventions). In study IV, information on maternal health during and after pregnancy was 
obtained from patient records and at a structured interview. At age 4 to 5 years, the children 
were assessed by a psychologist with a cognitive test (WPPSI-III). 
Results: In study I, we observed an increased risk of not receiving a final grade from com-
pulsory school for children exposed to ≥ 2 AED during pregnancy, adjusted odds ratio (OR) 
2.99 (95 % confidence interval [CI] 2.14–4.17), but no increased risk for children born to 
mothers with untreated epilepsy or exposed to AED in monotherapy. In study II, 22 % of 205 
infants  assessed with NAS had signs of mild neonatal abstinence and 3 % of severe absti-
nence. Among a total of 741 040 infants included in study III, 22 507 (3 %) were exposed to 
antidepressants during pregnancy. Thirteen percent of exposed infants were admitted to NCU 
compared to 8 % in the population, adjusted OR 1.5 (95 % CI 1.4-1.6). Respiratory disorders, 
persistent pulmonary hypertension and hypoglycemia were more common after maternal use 
of selective serotonin reuptake inhibitors. In study IV, there were no statistically significant 
differences in IQ between children born to women with mood disorders with lithium use 
during pregnancy (n=20), children born to mothers with mood disorders but no lithium use 
during pregnancy (n=8) and children born to mothers with no mood disorders (n=11). 
Conclusions: Neurotropic drugs during pregnancy can be associated to adverse outcomes in 
exposed children. Infants exposed to antidepressants have a moderately increased risk of be-
ing admitted to NCU. AED polytherapy during pregnancy may be associated to a worsened 
neurodevelopmental outcome but a causal connection is not established. Lithium exposure 
during pregnancy was not associated to adverse cognitive outcome at preschool age in our 
cohort.
6Lisa Forsberg, 2016
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I  INTRODUCTION
1.1 Principles of teratology
Teratology is defined as ‘the study of malformations or serious deviations 
from the normal type in developing organisms’ (1), i e the pathology of em-
bryology. James Wilson introduced six important principles of teratology (2). 
These principles, which still hold great relevance today (3), include: 
1. Susceptibility to teratogenesis depends on the genotype of the conceptus 
and the manner in which this interacts with environmental factors.
2. Susceptibility to teratogenic agents varies with the developmental stage at 
the time of exposure.
3. Teratogenic agents act in specific ways (mechanisms) on developing cells 
and tissues to initiate abnormal embryogenesis (pathogenesis).
4. The final manifestations of abnormal development are death, malforma-
tion, growth retardation, and functional disorder.
5. The access of adverse environmental influences to developing tissues de-
pends on the nature of the influences (agent).
6. Manifestations of deviant development increase in degree as dosage in-
creases from the no-effect to the totally lethal level (2).
Teratology research aim to investigate how different maternal, pregnancy- 
related and environmental factors, in association to fetal factors, can nega-
tively affect the development of the fetus. One important subgenre in this 
field is the study of pharmacological agents during pregnancy and how they 
affect the offspring. With the study of drugs during pregnancy also comes the 
inevitable study of the underlying conditions that are the indications for drug 
treatment and how that may impact the fetus. 
Teratology research is often associated to the study of congenital malforma-
tions (CM). The studies included in this thesis does not specifically study 
CM, but rather focuses on other outcomes such as neonatal morbidity and 
long-term health and development of children prenatally exposed to neuro-
tropic medications and maternal psychiatric disorders or epilepsy. These out-
comes are included in Wilson’s principle number four. 
The American Food and Drug Administration classify risks associated to drugs 
used during pregnancy and lactation. This system was recently changed and 
the new classification system provide information on drugs where the balance 
between risks associated to maternal illness as well as risks associated to the 
drugs are presented (4). Approximately half of all pregnancies in the US are 
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unplanned, which makes information on teratological properties of drugs an 
important matter not only for the pregnant population, but rather all women 
of child-bearing potential (5). In Sweden, an information database about risks 
of birth defects and adverse effects of drugs used during pregnancy, based on 
Medical Birth Register (MBR) data, is widely used clinically (6).
1.1.1 Congenital malformations
In 1961, William G McBride wrote a letter in The Lancet on observing a 
cluster of severe limb deformities in infants with intrauterine exposure to 
the drug thalidomide, used against pregnancy related nausea and vomiting 
(7). This was the start of a scandal with enormous human, societal and legal 
ramifications. It was also the start of intense research activity regarding drugs 
during pregnancy in general and drugs acting on the central nervous system 
(CNS) specifically (8). Surveillance of CM with birth/pregnancy registers 
was initiated, both drug specific registers such as the Lithium Register (9) 
and nation-wide registers, for example the Swedish MBR (10). Population-
based registers have the advantage of providing malformation data on a non-
exposed population which is highly relevant since major CMs are seen in 2-4 
% of all infants (11). Only approximately 5 % of all CM in the US are caused 
by environmentally associated teratogen agents (11). Ninety four percent of 
all CM occur in low and middle income countries (12). 
1.1.2 Pregnancy outcome and neonatal effects 
Besides structural CM, other important outcomes often studied in pregnant 
women with specific conditions or exposures are miscarriage or perinatal 
death, fetal growth, gestational length and Apgar score. Gestational length is 
a major determinant of neonatal and subsequent health of the child (12-14). 
Neonatal morbidity in infants prenatally exposed to drugs can be due to toxic 
effects of the drug, where the neonatal effect is similar to the pharmacological 
effects seen in treated patients, for example sedation after benzodiazepine or 
lithium exposure (15, 16). The effects may also be caused by the discontinua-
tion of the drug that occurs at the delivery, neonatal opioid abstinence is a 
typical example of this mechanism (17).
1.1.3 Long-term neurodevelopment
The brain is the target organ for many drugs and non-pharmacological sub-
stances that readily passes over the placenta, for example antidepressants, 
antiepileptic drugs or ethanol. Since the brain develops throughout the preg-
nancy, the influence of potential toxins must be evaluated with not only first 
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trimester use in mind (as is often the case with CM) (18). The immature and 
developing brain may also be more sensitive to these substances compared to 
the adult brain. Fetal Alcohol Syndrome (FAS) is a well-known example (19, 
20) and the increasing evidence of the negative effect on intelligence seen in 
children prenatally exposed to valproic acid (VPA) another one (21, 22). 
1.1.4 Considerations on lactation 
The studies included in this thesis do not directly address lactation and drug 
use. However, use of pharmacological agents during pregnancy and breast-
feeding are often discussed together in the literature as well as in the clinical 
situation. Lactation data for many drugs are limited. Milk:plasma ratio is of 
limited use if not infant blood/urine levels in nursed infants have been mea-
sured, to establish the relative dose that is being distributed to the infant (23). 
Several factors must be considered when clinical advice on breast-feeding 
and drugs are given: the benefits of breast-feeding to formula feeding, the 
potential negative effects of the drug distributed via breast milk and the risks 
for the mother should she refrain from the medication. The decision to breast-
feed or not may not be binary. In some cases, high peak levels can be avoided 
through careful timing of drug administration in relation to infant meals, in 
others, certain types of medication may be preferable to others within a drug 
class (24). Careful monitoring of the infant, sometimes with infant plasma 
levels, may be needed if breast-feeding is combined with certain drugs, for 
example lithium (25, 26). 
1.2  Chronic illness during pregnancy
Treating pregnant women with chronic conditions is a delicate medical task. 
Besides deep knowledge on how to treat the disease in question, it also re-
quires insight into how pregnancy may change the course of illness, how 
pregnancy can affect pharmacodynamics and pharmacokinetics of drugs used 
for treatment and how the illness and/or treatment options may affect the 
unborn child. The negative effects of a drug- or a poorly controlled maternal 
illness- varies with the stage of the pregnancy. In some cases, associations to 
other risk factors may need to be considered, for example a higher incidence 
of smoking in women with depression (8). Pregnant women with a complex 
medical history often require multidisciplinary teams working together to en-
sure optimal care during pregnancy. Ideally, the pregnancy is planned, the 
maternal health status as good as possible at the start of the pregnancy and un-
suitable drugs phased out and replaced before conception (27). Some women 
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may without consulting their doctor quit their medication once they become 
aware of the pregnancy. This may in the case of serious illnesses have dire 
consequences and is best avoided by preconception counseling (28).
1.2.1 Epilepsy
Epilepsy, a neurological condition defined by recurrent, unprovoked seizures, 
affect about 0.5- 0.9 % of the population (29). An estimated 0.3 to 0.4 % of 
pregnant women have epilepsy and the majority of them use antiepileptic 
drugs (AED) during pregnancy (30). The absolute risk for status epilepticus, 
stillbirth or maternal death is very low, but studies indicate increased mater-
nal mortality compared to the rest of the population (31-33). Pregnancy has 
previously been considered neutral with regard to seizure frequency (27, 34) 
but a recent study indicate that being pregnant per se impairs seizure control 
in women with epilepsy (WWE) (35). Untreated epilepsy does not entail an 
increased risk of major malformations but is associated to impaired seizure 
control (36).
1.2.2 Depression and anxiety disorders 
Major depressive disorder (MDD) is a common, potentially serious condition 
involving depressed mood but also an array of other symptoms. The diag-
nostic criteria according to the Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition (DSM-5) are summarized in Figure 1 (37). A global 
study ranked depression as the fourth leading cause of disease burden (38). 
Depression during pregnancy is a significant clinical problem. The prevalen-
ce varies greatly depending on disease definition and method of assessment 
(39-41). A systematic review found point prevalence of major and minor de-
pression during the first trimester to be 11 %, dropping to 8.5 % in the second 
and third trimester (41). Some studies suggest that up to 18 % of all women 
have a depressive episode during pregnancy (41). 
Anxiety disorders are also common in society (42). Generalized anxiety dis-
order (GAD) is the most common form of anxiety disorder in a primary care 
setting, whereas phobias are the most frequent forms in the general popula-
tion (42, 43). There is a large overlap between GAD and MDD, especially if 
lower diagnostic thresholds are applied (43). Anxiety disorders also include 
panic disorder, phobias including social phobia and agoraphobia, obsessive 
compulsive disorder and posttraumatic stress disorder (42). See figure 2 for 
definition of GAD (37). Anxiety disorders are also common during pregnancy 
(40, 44). High level of anxiety during pregnancy has been linked to postnatal 
depression and there is generally an overlap between anxiety and depressive 
symptoms (39). 
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A. Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms 
is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms 1-8 should 
be present nearly every day. 
1. Depressed mood most of the day. By self-report or observed by others.
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day. By self-report or observed by others.
3. Significant weight loss when not dieting or weight gain or decrease or increase in 
appetite.
4. Insomnia or hypersomnia. 
5. Psychomotor agitation or retardation (observed by others).
6. Fatigue or loss of energy.
7. Feelings of worthlessness or excessive or inappropriate guilt.
8. Diminished ability to think or concentrate, or indecisiveness.
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation wit-
hout a specific plan, or a suicide attempt or a specific plan for committing suicide.
B. The symptoms cause clinically significant distress or impairment in social, occupatio-
nal or other important areas of functioning.
C. The episode is not attributable to the physiological effects of a substance or to another 
medical condition.
D. The occurrence of the major depressive episode is not better explained by other men-
tal disorder. 
E. There has never been a manic episode or a hypomanic episode. (Note: all criteria 
except ‘E’ are included in the diagnostic criteria for major depressive episode included 
in bipolar disorders).
Figure 1. DSM-5 diagnostic criteria for Major Depressive Disorder (37)
A. Excessive anxiety and worry (apprehensive expectation), occurring more days than 
not for at least 6 months, about a number of events or activities.
B. The individual finds it difficult to control the worry. 
C. The anxiety and worry are associated with three (or more) of the following six symp-
toms (with at least some symptoms having been present for more days than not for 
the past 6 months):
1. Restlessness or feeling keyed up or on the edge.
2. Being easily fatigued.
3. Difficulty concentrating or mind going blank.
4. Irritability.
5. Muscle tension.
6. Sleep disturbance.
D. The anxiety, worry or physical symptoms cause clinically significant distress or im-
pairment in social, occupational, or other important areas. 
E. The disturbance is not attributable to the physiological effects of a substance or to 
another medical condition.
F. The disturbance is not better explained by another mental disorder. 
Figure 2. DSM-5 diagnostic criteria for Generalized Anxiety Disorder (37)
19
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Depression is treated with pharmacotherapy, psychotherapy or a combina-
tion of the two. Selective serotonin reuptake inhibitors (SSRI) are the most 
commonly prescribed antidepressants (45-47). Antidepressants are first line 
treatment for moderate to severe depression. Several forms of psychotherapy 
are recommended, either as single treatment for mild (to moderate) forms 
of depression or in combination with pharmacotherapy (48, 49). Cognitive 
Behavioral Therapy has so far the largest body of evidence but Interpersonal 
Therapy and short-term psychodynamic therapy are also effective treatment 
options (50, 51). 
Untreated mood or anxiety disorders during pregnancy involve risks to the 
mother as well as to the fetus. MDD, without exposure to antidepressants, 
have been linked to low birth weight and prematurity as well as neonatal 
symptoms in some but not all studies (52, 53). Also, maternal stress or ne-
gative life events have been associated to lower birth weight, lower gestatio-
nal age and changed response to painful stimulus in the infant (54, 55). The 
long-term neurodevelopmental effects associated to untreated maternal mood 
or anxiety disorders or prenatal exposure to antidepressants are not yet fully 
described. There are no conclusive evidence of negative effects (52).
1.2.2.1 Post-partum depression and post-partum psychosis
Post-partum depression (PPD) is often preceded by depression during preg-
nancy (39). The risk of MDD is however higher post-partum compared to 
before delivery and compared to the female population in general (40). Ina-
dequately treated PPD poses several risks for the mother and the infant, for 
example insecure mother-infant attachment (39, 56). Post-partum psychosis 
(PPP) is a rare but serious condition that is potentially life threatening to 
both mother and child (57). Properly diagnosed and treated PPP has a better 
long-term prognosis compared to other psychotic conditions but there is an 
increased risk of mania, depression or a second episode of PPP (58, 59).
1.2.3 Bipolar disorders
Bipolar disorders (BD) are a spectrum of disorders involving episodes of de-
pression, mania, hypomania and/or mixed episodes. Bipolar disorders are di-
vided into subgroups, the most important ones being bipolar disorder I (BDI) 
and bipolar disorder II (BDII) (37). BDI always include at least one episode 
of mania, while BDII involves at least one hypomanic episode and at least 
one major depressive episode (37, 49, 60). A worldwide meta-analysis found 
a point prevalence of 0.7 % (60), another survey a 12-month-prevalence of 
1.5 % for bipolar spectrum disorders, 0.4 % for BDI and 0.3 % for BDII (61). 
Figure 3 and 4 describe diagnostic criteria in DSM-5 for hypomanic or manic 
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A.  A distinct period of abnormally and persistently elevated , expansive or irritable 
mood and abnormally and persistently increased goal-directed activity or energy, 
lasting at least 1 week and present most of the day, nearly every day (or any duration 
if hospitalization is necessary). 
B.  During the period of mood disturbance and increased energy or activity, ≥ 3 of the 
following symptoms (4 if mood is only irritable) are present to a significant degree 
and represent a noticeable change from usual behavior: 
1. Inflated self-esteem or grandiosity.
2. Decreased need for sleep.
3. More talkative than usual or pressure to keep talking.
4. Flight of ideas or subjective experience that thoughts are racing.
5. Distractibility as reported or observed.
6. Increase in goal-directed activity or psychomotor agitation.
7. Excessive involvement in activities that have a high potential for painful conse-
quences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, foolish 
business investments).
C.  The mood disturbances is sufficiently severe to cause marked impairment in social or 
occupational function or to necessitate hospitalization or there are psychotic features.
D.  The disturbance is not attributable to the physiological effects of a substance or to 
another medical condition.
Figure 3. DSM-5 diagnostic criteria for Manic Episode (37)
A. A distinct period of abnormally and persistently elevated , expansive or irritable mood 
and abnormally and persistently increased activity or energy, lasting at least 4 conse-
cutive days and present most of the day, nearly every day. 
B. During the period of mood disturbance and increased energy and activity, ≥ 3 of the 
following symptoms (4 if mood is only irritable) have persisted and represent a noti-
ceable change from usual behavior: 
 1. Inflated self-esteem or grandiosity.
 2. Decreased need for sleep
 3. More talkative than usual or pressure to keep talking.
 4. Flight of ideas or subjective experience that thoughts are racing.
 5. Distractibility as reported or observed.
 6. Increase in goal-directed activity or psychomotor agitation.
 7. Excessive involvement in activities that have a high potential for painful conse-
quences.
C. The episode is associated with an unequivocal change in functioning that is uncharac-
teristic of the individual when not symptomatic. 
D. The disturbance in mood and the change in functioning are observable by others.
E. The mood disturbances is not severe enough to cause marked impairment in social 
or occupational function or to necessitate hospitalization. Psychotic features=manic 
episode. 
F. The disturbance is not attributable to the physiological effects of a substance or to 
another medical condition.
Figure 4. DSM-5 diagnostic criteria for Hypomanic Episode
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episode. Diagnostic criteria for major depressive episode included in BDI or 
BDII are listed in figure 1 (37).
Clinical management of pregnant women with BD poses similar treatment 
dilemmas as in the case of unipolar depression. However, the risks associa-
ted to the untreated illness are generally higher due to an often more severe 
condition and special attentiveness related to PPD or PPP is necessary (62). It 
has been demonstrated that women with BD are not protected against recur-
rence in mood episodes by their pregnancy but continuous mood stabilizing 
treatment is effective (63-65). 
1.3  Neurotropic drugs during pregnancy
Mood stabilizing drugs, AED, antidepressants and antipsychotic drugs are 
examples of neurotropic drugs, meaning substances with an affinity to the 
CNS. These drugs are of utmost interest during pregnancy, partly due to the 
fact that some of them are commonly prescribed in women of childbearing 
potential and partly due to the fact that neurotropic drugs may have unwanted 
and unpredictable effects on the immature, fetal brain (66). Below follows a 
brief presentation of the drugs studied in the included papers. 
1.3.1 Antiepileptic drugs
AED are used to prevent seizures in patients with epilepsy but also as mood 
stabilizing drugs in bipolar disorders. A large collaborative European data-
base study showed that 0.5 % of all pregnant women dispensed a prescription 
for an AED during pregnancy (67). The corresponding figure in Sweden 2007 
was 0.3 % (45). 
Many of the older AED have been associated to an increased risk of major 
CM, especially VPA, carbamazepine (CBZ) and certain polytherapy combi-
nations (68-72). Use of topiramate, a newer AED, in the first trimester has 
also been linked to increased risk of CM (73, 74).
A large overview by Källén et al concluded that there was no large increase of 
neonatal morbidity (excluding CM) associated to AED in general. However, 
VPA exposure increased the risk of preterm birth and neonatal diagnoses (8).
Exposure to AED during pregnancy may have a negative impact on neu-
rodevelopment. Many studies have linked VPA to autism or lower IQ (31, 
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75-79). CBZ has also been extensively studied but most studies have failed 
to show any effect on global cognitive abilities (79-82). Phenytoin (PHT) has 
been reported to have a negative influence on cognition (83, 84). Lamotrigine 
(LTG) does not seem to have a negative effect on neurodevelopment and leve-
tiracetam is not yet adequately investigated (85). Polytherapy have also been 
associated to negative neurodevelopmental effects (81, 83, 86). This associa-
tion may however be particularly difficult to investigate due to many different 
drug combinations and potential confounding by indication. Many studies of 
neurodevelopment and intrauterine exposure to AED have a relatively short 
follow-up period to evaluation and have limited power. Register studies, such 
as study I, is an important contribution to this field of research. 
1.3.2 Antidepressant drugs 
At present, around 4 % of pregnant women in Sweden and 6 % in the US un-
dergo treatment with antidepressant drugs (87-89) and this use is increasing 
(46, 88). However, the prescription of antidepressants is reduced during preg-
nancy compared to the months before and after pregnancy (45, 46).
1.3.2.1 Selective serotonin reuptake inhibitors
SSRI are the most commonly used antidepressant drugs during pregnancy 
(45, 90). They are prescribed for both depression and anxiety disorders. For 
most SSRI, there have been no association to major malformations although 
there have been conflicting reports about the risk of congenital heart defects 
after first trimester exposure to paroxetine, in some instances also fluoxetine 
(91-95). A recent meta-analysis concluded a slightly increased risk of major 
cardiac malformation after use of paroxetine, odds ratio (OR) 1.28 (95 % 
confidence interval [CI] 1.11-1.47) (96). 
Late pregnancy exposure to SSRI have been linked to an increased neonatal 
morbidity in numerous studies. The associated outcomes include respiratory 
distress, hypoglycemia and CNS effects, including seizures, as well as pre-
term birth, low birth weight and low Apgar scores (8, 90, 97-102). The neo-
natal symptoms, also called poor neonatal adaptation syndrome (PNAS), are 
mostly transient but may require neonatal care (103-105). Proposed mecha-
nism are withdrawal effects (98, 106) or serotonergic overstimulation syndro-
me (98). Pharmacogenetic variations in mother and/or fetus may contribute 
(107). Maternal depression in itself has been linked to poor neonatal adapta-
tion (52, 53) and efforts have been made to account for maternal illness in the 
study of potential pharmacological effects. In one study an increased risk of 
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respiratory disorders in infants exposed to SSRI was seen, even when com-
parisons were made to infants exposed to equal levels of maternal depression 
(108). SSRI exposure in utero has also been linked to persistent pulmonary 
hypertension in the newborn (PPHN), a rare but potentially serious condition 
(109, 110). Admittance rates to neonatal care in SSRI-exposed infants have 
not yet been described in a Swedish material and the severity of PPHN in this 
group needs to be further described in large cohorts. In study III, we aimed at 
increasing the knowledge on neonatal morbidity after intrauterine exposure 
to antidepressants. 
There are some studies of long-term neurodevelopment in children prena-
tally exposed to antidepressants and the majority of them have found similar 
cognitive development in exposed children compared to non-exposed peers, 
although subtle differences have been described (111-113). A study investiga-
ting child behavior reported that current maternal mood had an effect on ex-
ternalizing behavior of the child at four years of age but exposure to SSRI was 
not an important determinant (114). A Swedish, register-based case-control 
study found an association between autism spectrum disorders without intel-
lectual disability and maternal antidepressant drug use during pregnancy. A 
causal relationship is however not established (115).
1.3.2.2 Serotonin noradrenaline reuptake inhibitors and other newer 
             antidepressants
Serotonin noradrenaline reuptake inhibitors (SNRI) have a broader effect on 
neurotransmittors than SSRI and are often used as therapeutic alternatives to 
SSRI (49). Mirtazapine, venlafaxine and mianserin have both serotonin and 
noradrenaline inhibitory features whereas reboxetine is a selective noradrena-
line reuptake inhibitor. Exposure during pregnancy to these four drugs were 
associated to similar neonatal morbidity as SSRI exposure; preterm birth and 
hypoglycemia (116). No increased risk of malformations has been reported 
(116-118). Similar rates of transient neonatal symptoms were found after ven-
lafaxine and SSRI exposure (107).
Bupropion is a second line antidepressant treatment, but also an effective 
pharmacological tool in smoking cessation, possibly also in pregnant women 
(119). Although data are limited, an increased risk of cardiac malformations 
after first trimester exposure has been reported (120, 121).
1.3.2.3 Tricyclic antidepressants 
Prior to the introduction of SSRI, tricyclic antidepressants (TCA) were first 
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line of treatment for MDD. SSRI have a more favorable side effect profile 
and therefor, today, dominate the field (48). However, TCA remain as first 
line of treatment in severe, acute depression (48, 49). During recent years, the 
prescription of TCA have remained relatively unchanged in pregnant patients 
whereas a large increase of prescription of SSRI has been reported (46).
Clomipramine use during early pregnancy has been associated to an increased 
risk of cardiac malformations (8, 90). Neonatal morbidity, similar to that ob-
served after SSRI/SNRI exposure, have been reported after TCA exposure 
in late pregnancy (8, 122). A tendency towards worsened neonatal outcome, 
including neonatal diagnoses, prematurity and low birth weight, has been de-
scribed after TCA exposure compared to SSRI exposure, but this may be due 
to confounding by indication (8).
1.3.3 Mood stabilizing drugs
The treatment for BD focuses on acute stabilization, which means to bring a 
depressed or manic patient towards euthymic (stable) mood, and maintenance 
treatment, in which the goals are relapse prevention and reduction of mood di-
sorder symptoms. In bipolar depression, antidepressants have not been found 
as effective as in unipolar depression and the treatment is challenging (123). 
Lithium is the most established maintenance treatment and have been found 
effective in numerous studies (124). Side effects include negative effects on 
renal function, disturbances of the thyroid and parathyroid glands and weight 
gain. Lithium have a rather narrow therapeutic window and therapeutic drug 
monitoring is necessary (125). AED, for example LTG, can be used for mood 
stabilization but has less robust evidence compared to lithium (123). AED 
and pregnancy are discussed in section 1.3.1. Antipsychotic drugs have sound 
evidence in the treatment of manic episodes but less in mood relapse preven-
tion (123). Psychoeducation is also an important part of the therapeutic inter-
ventions in BD (126). 
1.3.3.1 Lithium 
Lithium completely passes over the placenta and umbilical cord concentra-
tions are similar to those in maternal blood (16). CM, especially cardiac mal-
formations and specifically Ebstein’s anomaly, a cardiac anomaly involving 
the tricuspid valve, have been linked to lithium exposure during pregnancy. 
Reports during the 1970’s described increased risks but later studies have 
modified this substantially and it is still debated whether first trimester ex-
posure to lithium in therapeutic doses constitutes an increased risk of cardiac 
malformations (125, 127-131).
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Increased risk of preterm delivery has been described in women with BD, re-
gardless of exposure to mood stabilizers (129, 131). Infants exposed to lithi-
um were found heavier than non-exposed infants in one study (132) but this 
was not repeated in a larger study (131). Neonatal morbidity related to fetal 
exposure to lithium has also been reported but the prevalence is not known. 
Lithium exposure has been associated to neonatal adaptation difficulties and 
symptoms such as poor muscle tone, lower Apgar score, cyanosis, hypothy-
roidism, neonatal diabetes insipidus, hypoglycemia, heart rhythm disturban-
ces and respiratory disturbances (16, 133). Close surveillance of maternal 
serum lithium levels during pregnancy is of great importance for the safety of 
both mother and infant (16). 
Current knowledge on long-term outcome after prenatal lithium exposure is 
limited. A study of 60 lithium-exposed children reported no difference in neu-
rodevelopmental outcome compared to their non-exposed siblings, however 
evaluation was based on maternal report only (134). Developmental milesto-
nes in 21 children were reported similar to a control group (132). A systematic 
evaluation of 15 children exposed to lithium in utero revealed no adverse 
effect on cognition or neurological development (135). High quality evalua-
tions of neonatal and long-term outcome of children prenatally exposed to 
maternal BD and lithium are needed. 
1.3.3.2 Antipsychotic drugs
Antipsychotic drugs, especially second generation antipsychotics (SeGA), 
are increasingly being used in BD and MDD (136). A recently published 
meta-analysis reported an increased risk of CM (no specific pattern) and pre-
maturity in SeGA exposed infants (137). Patients who use SeGA have a risk 
of substantial weight gain, insulin resistance and other metabolic side effects 
related to the medication (136). Increased risks of maternal gestational dia-
betes and neonatal respiratory disorders have been described after maternal 
use of antipsychotics (first generation antipsychotics, FGA, and SeGA) (138, 
139). Other types of neonatal behavioral signs, such as extrapyramidal signs, 
have been reported after exposure to both FGA and SeGA. These may not be 
as quickly resolving as PNAS reported after antidepressant exposure (140).
1.3.4 Other neurotropic drugs
In patients with psychiatric illnesses such as depression, anxiety disorders or 
BD, polypharmacy is common (141). In addition to antidepressants or mood 
stabilizers, other neurotropic agents such as pain medication, hypnotics or 
sedatives are used in the pregnant population (45, 142). 
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1.3.4.1 Hypnotics and sedatives
Benzodiazepines can be used as both sedatives/anxiolytics and hypnotics. 
They are commonly prescribed in combination with antidepressants. Prescrip-
tion of benzodiazepines was seen in 1.5 % of all pregnancies in a Norwegian 
register study (15). Exposure to benzodiazepines in utero has been linked to 
preterm birth, intrauterine growth restriction and PNAS (143) but no certain 
association to CM, although more than expected numbers of alimentary tract 
malformations have raised concern (143, 144). The combination of SSRI and 
benzodiazepines was in one study associated to an increased risk of cardiac 
malformations (145) but another study could not replicate the association (8). 
Hypnotic benzodiazepine receptor agonists are often grouped together with 
benzodiazepines but have also been evaluated separately in pregnant women. 
They do not seem to increase the risk of CM (142). 
Antihistamines are commonly used against nausea and vomiting during preg-
nancy but also have soporific properties which make them suitable for insom-
nia treatment in pregnant women. Antihistamines during the first trimester 
does not increase the risk of CM (146) and carries no risk for adverse delivery 
outcome according to Swedish register data (147).
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2.   AIMS 
2.1  General aims of the thesis 
The studies included in this thesis aimed at describing how neurotropic drugs 
and maternal chronic illness during pregnancy influence the health of the 
offspring, both neonatal and long-term outcome, with emphasis on neuro- 
development. 
2.1.1 Study I
We aimed to investigate academic achievement (school grades) at age 16 in 
children prenatally exposed to maternal epilepsy with or without antiepileptic 
drug exposure during pregnancy and compare them to non-exposed peers. 
2.1.2 Study II
Study II aimed to describe neonatal health in infants born to mothers who had 
used an antidepressant, SSRI or SNRI, during late pregnancy. We specifically 
studied neonatal diagnoses and behavioral scoring according to the Finnegan/
Neonatal Abstinence Score and made comparisons between infants exposed 
to different antidepressant drugs.
2.1.3 Study III
The aim of the study was to describe the severity of neonatal complications 
after fetal exposure to antidepressant drugs in a nation-wide, register-based 
cohort. The studied outcomes were admissions to neonatal care units, length 
of stay, neonatal diagnoses and interventions.
2.1.4 Study IV
We aimed at describing cognitive development and general health at pre-
school age in children prenatally exposed to maternal mood disorder, main-
ly bipolar disorder, with or without lithium exposure during pregnancy and 
compare them to unexposed children. Maternal psychiatric symptoms and 
neonatal health were also studied. 
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3.  METHODS
3.1  The register-based studies
In studies I and III we have combined information from national registers on 
health care (I and III) and education (study I) to answer our research ques-
tions. The included registers and study methods are described below. 
3.1.1 Registers
Sweden have a long tradition of collecting information about the health as 
well as the social and financial situation of its citizens in population-based 
registers (148). The National Board of Health and Welfare (‘Socialstyrelsen’) 
is generally responsible for registers concerning health and the health care 
sector. Statistics Sweden (‘Statistiska Centralbyrån’, SCB) compile large 
amounts of information on population and welfare, economical matters, re-
gions and environment, education and many other subjects (149) . Registers 
can be used for research purposes after application to the Regional Board 
of Ethics and the register holder. Linkage between different registers can be 
made using the personal identification number (PIN), a unique 10-digit num-
ber that all inhabitants of Sweden receive, either at birth or after immigration 
(150). 
3.1.1.1 The National Patient Register
The National Patient Register (NPR) was founded by the National Board of 
Health and Welfare in 1964 and initially described inpatient care for psychia-
tric and somatic care in parts of the country. The coverage of the register in-
creased gradually and in 1987, after a major revision, all counties of Sweden 
started reporting data on inpatient care (151). In 1983, approx. 85 % of all 
inpatient somatic care was reported to the register and in 2011, the coverage 
for somatic, inpatient care was almost 100 % (152). Since 2001, the register 
also contains information on public and private outpatient care. Primary care 
is not recorded in the NPR. The register contains information on main diag-
nosis, secondary diagnosis, length of hospital stay, procedures and age and 
sex of the patient (151). 
3.1.1.2 The Prescribed Drug Register 
The Prescribed Drug Register (PDR) contains information on drugs prescri-
bed and dispensed in ambulatory care in Sweden, covering more than 99 % 
of these prescriptions (153). This includes information on dose, substance 
and brand as well as PIN, age and sex of the patient and information about 
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the prescriber (154). In Sweden, epidemiological studies on drug use during 
pregnancy have extracted drug information from the MBR, available since 
1995, or the PDR, available since July 2005. The agreement between the PDR 
and the MBR is better for drugs used in chronic illnesses compared to short 
term treatments. The agreement for AED were 69 % and for antidepressants 
60 % (45). 
3.1.1.3 The Medical Birth Register
The MBR in Sweden was founded in 1973. It contains information on almost 
all pregnancies and deliveries in Sweden, only 0.5-3 % are missing com-
pletely (10). The information is extracted from the patient records filled out 
at the antenatal care clinics, delivery units and pediatric clinics. It contains 
information on maternal health and social situation during pregnancy and in-
clude for example smoking habits, body mass index (BMI), maternal age, 
mode of delivery, Apgar score of the infant, anthropometric data, gestational 
age (GA) and diagnostic codes according to the International Classification 
of Disease (ICD) for mother and infant. From 1995 and onward, information 
on maternal medication at the first visit to the antenatal care clinic and at GA 
32 was included and computerized (10). 
3.1.1.4 The Swedish Neonatal Quality Register 
The Swedish Neonatal Quality Register (SNQ) started in 2000 in order to 
provide detailed information on neonatal care for the purpose of improving 
care and facilitating research. By 2004, 21 out of then 34 neonatal units repor-
ted all their patients to the register (155). It contains information on newborn 
infants admitted to a neonatal ward at birth or within 28 days of birth. Today, 
all 37 neonatal units in Sweden are included. The register contains medical 
information on diagnoses, procedures, feeding, respiratory support, pharma-
cological treatments, duration of stay and many other variables (156, 157). 
Diagnostic criteria are predefined (155).
3.1.1.5 The Perinatal Revision South Register 
The Perinatal Revision South (PRS) database comprises obstetric and neona-
tal data from all maternity units in the southern Swedish region. PRS was es-
tablished in 1995 with quality assurance of perinatal and neonatal care as the 
main purpose (158). In 1995, there were 11 obstetrical units but since then, 
four of them have closed. Neonatal data are sent from all seven neonatal units 
in the region. Since 2005, all data are sent electronically and since 2012, PRS 
data are included in SNQ (159). 
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Figure 5. Patients and data collection in study I.
Figure 6. Patients and data collection in study III.
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3.1.1.6 The Swedish School Mark Register 
The Swedish National Agency for Education compile statistics from all Swe-
dish schools on grades from compulsory school as well as upper secondary 
school and adult education. This has been done since 1988 and is published 
once per year. Information from the register can, after application to Statistics 
Sweden, be available for research purposes. The register holds information on 
grades in specific subjects as well as on leaving certificates (LC)/final grades 
(160). 
3.1.1.7 The Swedish Register of Education
This register contains information on highest level of education attained by 
all residents of Sweden, aged 20-74 years. It started in 1985 and is since then 
updated once per year. The level of education is divided into six levels: 1=pri-
mary and lower secondary education less than 9 years, 2= primary and lo-
wer secondary education, 9 (or 10) years, 3=upper secondary education (2-3 
years), 4=post-secondary education <2 years, 5=post-secondary education ≥2 
years, 6=postgraduate program (161).
3.1.2 Patients and data collection
Exposures, co-variates and outcomes analyzed in the two register-based stu-
dies (I and III) as well as data sources are summarized in figure 5 and 6. 
3.1.2.1 Study I
In study I, the MBR and the NPR were used to identify WWE who had been 
giving birth during 1973 to 1986. Women with a diagnostic code of epilepsy 
(ICD code) and hospital care in the NPR between 1973 and 1989 were iden-
tified as WWE. WWE who had been included in a clinical study at South 
Hospital in Stockholm, conducted 1984-1995 and women with a diagnosis 
of epilepsy in the MBR were also included (80). The children of WWE were 
compared to the rest of the population. 
Information on maternal use of AED during the first trimester of the preg-
nancy was retrieved from the maternal care records. Variables relating to de-
livery and baseline maternal data were added from the MBR and maternal 
education level from the Swedish Register of Education. Information on the 
outcome, the school grades at the end of compulsory school at approx. 16 
years of age, was taken from the Swedish School Mark Register. The different 
registers were linked together with a combination of mother’s date of birth, 
date of delivery, delivery hospital, infant sex and birth weight which gives a 
full identity without the use of PIN. 
32
Lisa Forsberg, 2016
3.1.2.2 Study III 
The study population consisted of all singleton, live births in Sweden, regis-
tered in the MBR between 1 July, 2006 and 31 December, 2012. Using PIN 
for linkage, we could add information on maternal drug use during pregnancy 
from the PDR and the MBR. Data on neonatal outcomes were collected from 
the SNQ, the PRS and the MBR. 
The studied antidepressant agents were divided into the following subgroups 
based on their pharmacological properties: SSRI, TCA, SNRI, mirtazapine/
mianserin and other antidepressants, (moclobemide, bupropion, reboxetin 
and agomelatin). The use of antidepressants was allocated into any use: drugs 
dispensed 1 month before and at any time during the pregnancy, late use: 
drugs dispensed during the last 90 days of the pregnancy and early use only: 
drugs dispensed 1 month before and during pregnancy but not for the last 90 
days of the pregnancy. 
The neonatal outcomes studied included information from both ‘checkboxes’ 
and ICD-codes from SNQ and PRS as well as ICD-codes from the MBR. 
Since SNQ only contains information on infants admitted to a neonatal care 
unit (NCU), the inclusion of information from the MBR meant that we also 
had information on children with neonatal morbidity who remained in the 
maternity ward. Of course, the outcome ‘neonatal care’, length of stay and 
information on ventilator/CPAP (Continuous Positive Airway Pressure) was 
only available for children admitted to NCU. 
3.1.3 Statistical methods
3.1.3.1 Study I 
We compared children of WWE to all other children in the cohort using the 
Mantel-Haenszel analysis and adjusting for child’s year of birth, maternal 
age, parity and maternal level of education. Risks were expressed as OR, and 
95 % CI were estimated using Miettinen’s method. Two ORs were compared 
as two-tailed z tests based on the estimated variances.
3.1.3.2 Study III
Logistic regression analyses were used to compare dichotomous outcomes. 
In the different analyses, we compared any antidepressant versus no use, the 
individual antidepressant substances versus no use, or late use versus early 
use only. Multivariate analyses were performed with ‘maternal’ and ‘fetal’ 
factors included, presented in Figure 6. Differences regarding the length of 
stay at the neonatal unit, the number of days on ventilator or CPAP respec-
tively, were evaluated using Mann-Whitney U tests or Kruskal-Wallis tests 
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(non-parametric tests). Statistical analyses were made using SPSS (version 
22) and GaussTM (Aptech Systems Inc., Maple Valley, WA, USA, http://
www.aptech.com, version 10).
3.2  The clinical cohort studies
Studies II and IV were clinical cohort studies. Mother-infant pairs were divi-
ded into groups by maternal illness or neurotropic drug use during pregnancy 
and studied with regard to neonatal (studies II and IV) and long-term health 
(study IV). 
3.2.1 Study II
This study was a retrospective cohort study investigating neonatal health in 
children exposed to antidepressant drugs during pregnancy.
Figure 7. Patients included in study II. Infants born to mothers with use of  
  antidepressants during pregnancy.
3.2.1.1 Patients
The study patients were identified in the integrated electronic patient record 
used in the delivery and prenatal care units as well as for outpatient maternal 
visits (Obstetrix 2.12.01.100, Siemens AG, Munich, Germany). Patients with 
diagnostic codes for psychiatric illness during pregnancy and exposure to fe-
tus of pharmacological substances were selected as the study population. Wo-
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men fulfilling these criteria and who had been giving birth at the Karolinska 
University Hospital Huddinge between 1 January, 2007 and 30 June, 2009 
were included. Women with other relevant neurotropic medications (AED, 
lithium or opioids), substance abuse or missing data from large parts of the 
health care records were excluded. Final study population is described in 
figure 7. 
3.2.1.2 Data collection
Data was collected from the electronic health care records on social situation, 
prenatal medication (antidepressants and other pharmacological substances), 
health status including obstetrical health and mode of delivery. The source 
of information in the health care records were the prenatal care visits where 
standardized forms are used and large amounts of information on maternal 
health is gathered. Antidepressant use was defined as the type of antidepres-
sant used in the third trimester. Health care records were also scrutinized for 
information on neonatal health including, but not limited to, ICD codes for 
neonatal morbidity such as hypoglycemia (defined as a blood glucose level 
< 2.6 mmol/L), respiratory disorders and admittance to NCU.
3.2.1.2.1 Neonatal Abstinence Score
During the study period, all infants where the mother had reported antide-
pressant use during late pregnancy were routinely observed at the maternal 
ward for at least 72 hours and modified Finnegan score (Neonatal Abstinence 
Score, NAS) used regularly to detect signs of abstinence. NAS was originally 
developed to diagnose abstinence in infants prenatally exposed to opioids 
(162), but has also been used to assess neonatal symptoms in SSRI-exposed 
infants (163). A version re-translated into English from Swedish is showed 
in figure 8 (164). The assessment includes four categories: CNS, respiratory, 
gastrointestinal and ‘other symptoms’, maximum score 41 points. Neonatal 
abstinence was in this study classified as either mild (score ≥4 on ≥2 occa-
sions) or severe (score ≥8 on ≥2 occasions).
3.2.1.3 Statistical methods
Logistic regression was used to compare dichotomous outcomes between the 
different types of antidepressant exposures in a multivariate model (neonatal 
care, hypoglycemia, respiratory diagnosis). Kruskal-Wallis was used to com-
pare time to ‘peak score’ of NAS and blood glucose levels in hypoglycemic 
infants between the exposure groups. We used ordinal regression to compare 
the rates of ‘no abstinence’, ‘mild abstinence’ and ‘severe abstinence’. OR in 
ordinal regression describes the odds to move one step up on an ordinal scale. 
Statistical analyses were performed using StatisticaR 64, version 12 (Statsoft 
Scandinavia AB, Uppsala, Sweden).
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Figure 8. Neonatal Abstinence Score. Modified from Finnegan to Swedish by I Sarman  
               (164) here re-translated.
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3.2.2 Study IV
This study was a clinical cohort study on neonatal health as well as cognitive 
and general health at preschool age in children born to women with severe 
mood disorders with or without lithium during pregnancy. 
3.2.2.1 Patients
The cohort consisted of two groups of mother-child pairs: women with mood 
disorders (maternal mood disorder, MMD) and women without mood disor-
ders (no MMD). The first group was further divided into two: with or without 
lithium use during pregnancy. Patients with mood disorders were recruited 
from the Affective Disorder Outpatient Clinic, Psychiatry Southwest, Stock-
holm. The children were born between 2006 and 2010 and the mothers were 
offered participation when the child was four to five years old. Women wit-
hout mood disorders were identified through the electronic health care record 
Obstetrix© and offered to participate. They were matched for maternal age, 
child’s date of birth and child’s sex. Maternal psychiatric illness and/or treat-
ment during pregnancy were exclusion criteria. 
3.2.2.2 Data collection
Information on maternal psychiatric health during pregnancy, including phar-
macotherapy, lithium serum levels and obstetrical information was obtained 
retrospectively from a clinical register held at the outpatient clinic and from 
patient records. Neonatal morbidity, diagnoses, laboratory measurements and 
treatments was collected from electronic health care records (Obstetrix©). In-
formation on thyroid stimulating hormone (TSH) from the neonatal screening 
was obtained from the PKU register, Center for Inherited Metabolic Diseases, 
Karolinska University Hospital.
The prospective part of the study included one or two research visit(s) at 
Karolinska University Hospital Huddinge. A researcher performed a stan-
dardized interview with the mother regarding maternal and child health and 
the social situation of the family and distributed several self-evaluation ques-
tionnaires: PHQ-9 (current symptoms of depression), AUDIT (alcohol use 
disorders identification test) and DUDIT (drug use disorders identification 
test). At the same visit, the child was examined by a pediatrician and blood 
tests drawn (kidney- and thyroid tests). He or she was also evaluated by a 
child psychologist (blinded to exposure to maternal illness or medication), 
using the Wechsler Preschool and Primary Scale of Intelligence, 3rd edition 
(WPPSI-III). All children but one, who had recently been tested in a clinical 
setting by a different psychologist, were tested by the same psychologist. 
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3.2.2.2.1 Wechsler Preschool and Primary Scale of Intelligence, 3rd edition
WPPSI-III is a standardized psychological instrument used to evaluate cog-
nition in children between the ages 2 years and 6 months to 7 years and 3 
months. The test results are presented as Full Scale IQ, FSIQ, which con-
sists of seven subtests (three verbal, three non-verbal subtests and one subtest 
also included in the processing speed quotient, PSQ), Verbal IQ, VIQ (three 
subtests), and Performance IQ, PIQ (three subtests on non-verbal problem 
solving). PSQ consists of the results from two subtests. WPPSI-III IQ values 
are tested in a normal population and mean values are 100, standard deviation 
(SD) 15 (165). 
3.2.2.3 Statistical methods
Fisher’s exact test was used for dichotomous outcomes, Kruskal-Wallis or 
Wilcoxon rank sum test for continuous variables. Spearman’s correlations 
test was used in testing correlation between maternal and infant lithium con-
centration. In statistical testing of the WPPSI-III results we used regressi-
on models for PIQ. Due to non-ignorable missing data (three children had 
missing values for VIQ, four for FSIQ and seven children had missing values 
for PSQ) a Tobit regression model was used to analyze VIQ, FSIQ and PSQ. 
Using this model we assumed that the missing value was at most the same va-
lue as the lowest recorded value for that variable. We chose the confounders 
in the regression analyses by testing them in a separate model, one by one, 
against PIQ, VIQ, FSIQ and PSQ and including variables with a p-value < 0.2 
in any of the analyses. In all other statistical tests of our results, a significance 
level of p < 0.05 was used. Data were analyzed using Stata (Statacorp, Texas, 
USA, version 13.1). 
3.3  Ethical considerations
Research concerning personal information such as reproductive history, soci-
oeconomic situation, psychiatric health and family situation are of a sensitive 
nature. All patient material in the presented studies have been handled with a 
high level of confidentiality, as stated in the ethical permits. In studies I and 
III, population-based registers containing large amounts of patient data have 
been linked together and analyzed without personal identification numbers in 
the analytic phase. In study II, patient records were scrutinized by one resear-
cher (LF). No individual patient consent was given or requested in study II, 
in accordance with the ethical permit. In study IV, all women gave informed 
consent to their own study participation and all legal guardians of participa-
ting children gave informed consent to their child’s participation. 
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Ethical permit, study number I: 2006/673-31/4, Regional Ethics Board, Stock-
holm, Sweden; study II: 2010/686-31/2, Regional Ethics Board, Stockholm, 
Sweden; study III: 2013/342, Regional Ethics Board, Lund, Sweden; study 
IV: 2011/96-31/2 and amendment 2011/1144-32, Regional Ethics Board, 
Stockholm, Sweden. 
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4.  RESULTS
4.1  Intrauterine exposure to neurotropic drugs and neonatal 
       effects 
Study II, III and IV investigates how neurotropic drugs during pregnancy, 
especially the last part of the pregnancy, can affect neonatal morbidity. Study 
II and IV are smaller but more controlled cohorts whereas study III describes 
a large, population-based cohort. They all include children born to mothers 
with mood disorders or anxiety disorders. 
In study II, the study population consists of 220 infants born to mothers with 
antidepressant medication during pregnancy. 77 were exposed to citalopram, 
76 to sertraline, 34 to fluoxetine and 33 to ‘other antidepressants’ (escitalo-
pram, n=13, venlafaxine, n=11, paroxetine, n=8, and duloxetine, n=1).
 
In study III, the study population consisted of 741040 singleton births, of 
which 22 507 (3.0 %) were exposed to antidepressants. The most common 
drug group was SSRI with 17 736 exposures (2.4 %).
The patient cohort in study IV were 24 mothers with MMD and their 28 
children (one set of twins, three sibling pairs) and 11 no MMD mother-child 
pairs. 20 children had been exposed to lithium during pregnancy, 8 had been 
exposed to MMD but no lithium and 11 no MMD. There was no information 
on obstetrical care and the neonatal period in one mother-child pair (MMD + 
lithium group).
4.1.1 Neonatal care 
In study II, we could describe an admittance rate to NCU of 13 %, with no 
statistically significant differences in admittance rates between infants expo-
sed to citalopram, sertraline, fluoxetine or ‘other antidepressants’. We did not 
have a proper control group but data from SNQ showed an admittance rate 
for Karolinska University Hospital Huddinge for the years 2007-2009 of 10 
%, this difference was not statistically significant in a univariate analysis, 
p= 0.16. 
After study II, we decided to move on to a nation-wide, register-based study 
of infants exposed to antidepressants in utero. In study III, SNQ in combina-
tion with MBR and PDR provided us with a dataset that had adequate power 
to find differences between exposed and non-exposed children but also pos-
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sible drug-class specific effects. We made comparisons both between the ex-
posed children and the non-exposed population as well as between infants ex-
posed in early and late pregnancy. The latter analysis was an attempt to adjust 
for maternal psychiatric morbidity. In the analysis of early vs late exposure 
a significant heterogeneity was found between all five antidepressant groups, 
p= 0.002. ORs were highest for TCA and SNRI exposed infants. 
Table 1 describes neonatal care in infants exposed to antidepressants vs non- 
exposed infants. When antidepressant drug treatment was combined with 
other neurotropic drugs – most commonly opioids, neuroleptics or sedatives 
– 16 % of the neonates were admitted to NCU; OR 1.8 (95 % CI 1.7-1.9, 
adjusted for maternal factors). When early and late use of antidepressants 
were compared there was also significantly increased odds for neonatal care, 
OR 1.7 (95% CI 1.6-1.9, adjusted for maternal factors and use of other neu-
rotropic drugs). Number needed to harm (NNH) was 15 (adjustment for ma-
ternal factors and use of other neurotropic drugs did not change the estimate). 
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Duration of neonatal care was significantly shorter for infants exposed to anti-
depressants compared to non-exposed infants (p< 0.001). 
In study IV, 3/19 infants in the MMD and lithium group were admitted to 
NCU, 3/8 infants in the MMD and no lithium group and 2/11 in the no MMD 
group, these differences were not statistically significant (p= 0.5). Among 
full-term infants only, there were NCU admissions in 2/18 in the MMD and 
lithium group, 0/5 in the MMD and no lithium group and 1/10 in the no MMD 
group. 
4.1.2 Neonatal Abstinence Score
In study II, NAS scoring was performed in 205 infants out of 220 exposed to 
antidepressants. Mild abstinence/maladaptation (score 4 and above on at least 
two occasions) was seen in 22 % and severe (score 8 and above on at least 
two occasions) in only 3 %. There were no statistically significant differen-
ces in occurrence of mild or severe abstinence between the different types of 
antidepressant exposure (p=0.85, ordinal regression, adjusted for infant sex 
and 5 min Apgar). 
4.1.3 Neonatal morbidity
In study II, III and IV, several diagnoses or groups of diagnoses have been 
studied in infants prenatally exposed to neurotropic medications.
4.1.3.1 Hypoglycemia
In study II hypoglycemia was seen in 19 % of all study subjects (42 patients), 
significantly more prevalent in infants exposed to fluoxetine (35 %) compa-
red to citalopram (11 %), multiple regression model adjusting for GA, 5 min 
Apgar, maternal smoking, infant sex, p= 0.01. In study IV, neonatal hypogly-
cemia was seen in 2/18 children in the group exposed to MMD and lithium, 
2/8 in the MMD and no lithium group and 1/11 in the no MMD group, p= 
0.84. 
In study III, the incidence of hypoglycemia was 4 % in infants prenatally 
exposed to SSRI compared to 2.4 % in the general population, OR 1.3 (95 % 
CI 1.2-1.4, adjusted for maternal factors and use of neurotropic drugs). Ad-
justed OR, late use vs early use only of SSRI for hypoglycemia was 1.5 (95 
% CI 1.3-1.7). In the comparison between late and early use, there was also 
an increased risk of feeding difficulties, adjusted OR 1.7 (95 % CI 1.3-2.3). 
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4.1.3.2 Respiratory disorders
In study II, a respiratory diagnosis was seen in 14 out of 220 infants (6 %), no 
significant differences between the exposure groups (p= 1.0, logistic regres-
sion adjusting for 5 min Apgar and GA). In study IV, three children exposed 
to MMD and no lithium and one child born to a mother with no MMD had a 
respiratory diagnosis. All four children were born preterm (one pair of twins). 
There was an increased risk of respiratory diagnoses in infants prenatally ex-
posed to SSRI in study III. Transient tachypnea and other respiratory diagno-
ses (not including meconium aspiration syndrome, PPHN or respiratory dist-
ress syndrome (RDS)) was more common in SSRI-exposed infants compared 
to the general population, OR 1.7 (95 % CI 1.6-1.9, adjusted for maternal 
factors and use of neurotropic drugs) and in early vs late use, OR 1.7 (95 % CI 
1.5-2.0, adjusted as above). RDS was not more common in SSRI-exposed in-
fants compared to non-exposed, OR 1.0 (95 % CI 0.8-1.2, adjusted as above). 
CPAP treatment was more common in SSRI-exposed infants compared to 
non-exposed, OR 1.5 (95 % CI, 1.4-1.6, adjusted as above). 
4.1.3.3 Persistent pulmonary hypertension
PPHN was more common both when comparing SSRI-exposure to non-expo-
sure; OR 1.3 (95 % CI 1.0-1.6, adjusted as above) and treatment during late vs 
early pregnancy; OR 2.1 (95 % CI 1.3-3.2, adjusted as above). The correspon-
ding NNH was 285, comparing late and early exposure, adjusted for maternal 
factors and neurotropic drugs. Restricting the analysis to full-term infants, 
the association between SSRI, late vs early use, and PPHN was even more 
pronounced; OR 2.6 (95 % CI 1.4-4.8). NNH was however larger, 322, due to 
lower absolute risk. The mortality rate among infants with PPHN was 3.4 % 
(3/89) for SSRI-exposed and 8.3 % (171/2051) for non-exposed infants. This 
difference was not statistically significant, OR 0.4 (95 % CI 0.1-1.2). 
4.1.3.4 CNS-related disorders
In study II, where NAS was used to assess poor neonatal adaptation in expo-
sed infants, CNS-related symptoms accounted for 67 % of the scoring points 
in the group with severe abstinence and 58% in the group with mild absti-
nence. 
In study III, separate analyses were made for CNS-related disorders (seizu-
res, muscle tone disturbances, withdrawal symptoms, disturbances of cere-
bral status, hypoxic ischemic encephalopathy) and intracerebral hemorrhage 
(ICH). CNS-related disorders were more common both when SSRI-exposed 
infants were compared to non-exposed as well as in the comparison of early 
vs late use, in the latter analysis; OR 2.0 (95 % CI 1.3-3.1, adjusted for ma-
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ternal factors and neurotropic drugs). There was no increased risk of ICH in 
any of the analyses. 
4.1.3.5 Thyroid disorders 
In study IV, TSH levels from the neonatal screening was available for 38/39 
children. None of the children had abnormal values. In the child with a missing 
value in the neonatal screening, a normal TSH (3.8 µU/ml) was analyzed in 
the neonatal period. TSH analysis due to maternal lithium treatment was done 
in another 7 cases (no neonatal data in one child) and among them, one child 
had a TSH of 37 µU/ml at two hours of age, but the result was normalized 48 
hours later. All other values were within normal limits.
4.1.3.6 Drug concentration measurements
Study IV was the only study where drug concentration measurements of mot-
her and child were available. Lithium concentrations were repeatedly mea-
sured during pregnancy, see section 4.3.2. Sixteen infants (out of totally 20 
mother-child pairs with lithium during any part of the pregnancy) were ex-
posed to lithium during the third part of the pregnancy. In seven of these 
infants, lithium serum concentrations were analyzed in umbilical cord blood 
samples and for two of them, measurements were repeated during the neona-
tal period. Cord blood lithium concentrations ranged between 0.28 and 1.57 
mmol/L, median 0.6 mmol/L. In one child exposed to lithium, no cord blood 
was sampled but serum lithium concentration was 0.6 mmol/L two hours after 
birth. In the eight infants with neonatal blood samples available, last mater-
nal samples before delivery were between 0.26 and 0.8 mmol/L. Correlation 
between last maternal sample and cord blood value of lithium was low, R= 
0.25 (p= 0.58). 
4.2  Intrauterine exposure to neurotropic drugs and effects on 
       long-term development
Two of the included studies aim to describe the potential effects of neuro-
tropic drugs on long-term development of the exposed child, with special 
emphasis on neurodevelopment. In study I, this is investigated through school 
performance, measured by final grades from last year of compulsory school 
and in study IV by psychological testing and parental interview. 
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Figure 9.  Patient material in study I. Children born to mothers with epilepsy, 1973  
to 1986.
4.2.1 Antiepileptic drugs and school performance 
Figure 9 describes the study population of study I. The final study population 
consisted of 1235 children born to WWE and 1 307 083 children born during 
the same study period to mothers with no record of epilepsy. 
The school results of the study population is analyzed with regard to not get-
ting a LC and school grades in English, Swedish, Mathematics and Sports, the 
latter divided into passed, passed with excellence and not passed, see Table 
2 and 3. To not receive a LC means to have no grade in any subject, in most 
cases indicative of very high level of absence or special school attendance. 
In Mathematics, English and Swedish, children exposed to CBZ had statisti-
cally significant lower odds of receiving a ‘pass with excellence’ compared to 
those exposed to PHT. 
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     ORs adjusted for child’s year of birth, maternal age, parity and maternal education level
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4.2.2 Lithium, maternal mood disorders and general health
In study IV, fifteen of the included 39 children had a physical or developmental 
disorder according to the parental interview. There were five cases of asthma, 
all with intermittent treatment, four born to mothers with MMD (n=28) and 
one in the control group (n=11). Two children (one in each exposure group) 
had allergies. Three children in the MMD group had dermatological condi-
tions. Two children had ear problems (one in each exposure group). Three 
children, all in the MMD and lithium group, had speech/language difficulties 
and were seen by a speech therapist. Two of these children (both of whom did 
not have Swedish as a first language) had low or no result on the verbal tests 
in WPPSI-III but one child had seen the speech therapist due to pronunciation 
difficulties and had a high VIQ. One child exposed to MMD and no lithium 
had been diagnosed with ADHD (Attention Deficit Hyperactivity Disorder) 
and one child in the control group had an unclassified neurological condition 
with gross and fine motor difficulties. 
4.2.3 Lithium, maternal mood disorders and psychological test results
Results from the WPPSI-III test were available for all 39 participating child-
ren. The crude results are summarized in table 4 and the statistical models 
(linear regression models and Tobit regression models) in table 5. Table 5 
both include a statistical model comparing the different exposure groups and 
a model comparing the results of the different groups to IQ 100. 
There were no statistically significant differences between children exposed 
to MMD (with or without lithium) and the ‘control’ group when PIQ, VIQ 
and FSIQ were compared. PSQ results were significantly lower for children 
exposed to MMD with (p= 0.05, crude analysis) and without lithium (p= 0.04, 
crude analysis) compared to children not exposed to MMD.
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4.3 Maternal health and risk factors
Maternal health and maternal risk factors relevant to infant/child health was, 
to some extent, described in all the included studies. 
4.3.1 Baseline data and risk factors in participating mothers
In study I, all ORs presented above are adjusted for maternal age, parity, ma-
ternal level of education and child’s year of birth. 
Study II contains information on several maternal risk factors for neonatal 
morbidity, including BMI, maternal smoking and age. Cigarette smoking in 
early pregnancy was seen in 13 % of the women included in the study, com-
pared to 4.7 to 5.4 % for pregnant women in the entire Stockholm area, 2007-
2009. BMI was higher in the cohort, 24.4 kg/m2, compared to all women who 
gave birth in the Stockholm area 20007-2009 (23.8-23.9 kg/m2). Note that the 
catchment area of Karolinska University Hospital Huddinge is demographi-
cally different compared to the rest of Stockholm County. 
In contrast to study II, study III contain information on both women with 
antidepressants and women without antidepressants during pregnancy. To 
summarize background data (table 1 in the paper), women with antidepres-
sants were more likely to be over 35 years of age (OR 1.3, 95 % CI 1.3-1.4), 
smokers (OR 2.7, 95 % CI 2.6-2.8) and obese (OR 1.6, 95 % CI 1.5-1.7) but 
less likely to be born in a non-Nordic country (OR 0.5 95 % CI 0.5-0.5). 
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Study IV also contains information on risk factors for the subsequent health 
of the child. Table 1 in the manuscript describes maternal characteristics for 
the three exposure groups. There were no mothers in any of the groups who 
smoked cigarettes during pregnancy (asked at research interview). Seventeen 
out of twenty in the lithium and MMD group and all mothers in the other 
two groups lived with the father of the child at the time of delivery. Among 
women with mood disorder, 67 % (18/27) had a post-secondary education, 
compared to 55 % (6/11) in the no MMD group. Polypharmacy was common 
in the MMD group, 15/27 women had two or more neurotropic drugs during 
pregnancy. None of the other types of drug exposure (LTG, antipsychotic 
drugs, hypnotics, antidepressants, antihistamines, benzodiazepines and other 
pharmacological substances) were associated to significantly lower child PIQ. 
4.3.2 .Maternal psychiatric health during pregnancy 
Table 6 summarizes information on psychiatric health during and after preg-
nancy for the mothers included in study IV. The majority of the participating 
mothers in the MMD groups, 25/27, had BD I or II. Two women had recur-
rent depression. Nine patients in the MMD and lithium group had episodes of 
depression during pregnancy, two of them also had an episode of hypomania. 
In the MMD and no lithium group, one mother had an episode of hypomania 
and one had a depressive episode during pregnancy. 
In the 20 women who were treated with lithium during some part of pregnan-
cy, a total of 183 lithium serum level values were measured during pregnancy, 
ranging between 0.07 and 1.3 mmol/L. Mean value 0.47 mmol/L, SD 0.20, 
median 0.4 mmol/L. Maternal lithium concentrations during pregnancy are 
summarized in figure 10. 
4.3.3 Maternal psychiatric health at follow up
In study IV, median time in mood disorder episode after delivery was 8 
months for women with MMD and no lithium during pregnancy compared to 
median 1 month for the MMD and lithium group, approaching statistical sig-
nificance, p= 0.06. The results for the depression scale PHQ-9 also indicated 
a more favorable situation for the women using lithium prenatally compared 
to the MMD and no lithium group, see table 6, but this was not statistically 
significant, p= 0.12.
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Figure 10.  Maternal lithium concentrations (mmol/L) in the twenty women using lithi-
um  during any part of the pregnancy, by post-menstrual time (days), study 
IV. The grey and dotted lines are individual women’s serum concentrations, 
the black line the predicted trajectory of all patients.
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5.  DISCUSSION 
5.1  General discussion 
Neurotropic drugs during pregnancy is a research area that attracts attention, 
and rightfully so. Pregnant women, just like all other patients, deserve evi-
dence-based care for physical and mental illnesses and effective treatment op-
tions should be evaluated for this specific group. However, this is a lot easier 
said than done. Out of concern for the fetus, pregnant women are often reluc-
tant to continue or initiate drug therapy during pregnancy. Health care pro-
fessionals sometimes apply the ‘better safe than sorry’ approach to pregnant 
women and advise against pharmacotherapy during pregnancy. This may, in 
the case of mild conditions where pregnancy data on the drug are limited (or 
include known negative effects), be correct. In the case of potentially serious 
conditions such as epilepsy or bipolar disorder, advice to abstain from phar-
macotherapy during pregnancy may have severe consequences for both mot-
her and child (64, 68). On the other hand, some drugs have teratogenic pro-
perties and exposure during pregnancy can have lifelong ramifications. This 
delicate balance is something that clinicians treating pregnant women with 
chronic illnesses are dealing with on a daily basis. For a researcher within this 
field, all results must be interpreted with this balance in mind. A vast majo-
rity of the research performed on humans on pharmacological substances and 
pregnancy are observational studies with many methodological challenges. 
Randomized controlled trials are often described as impossible to perform 
in a pregnant population but some authors conclude that they are ethical and 
feasible in women with depression (166). 
5.2  Discussion on neurotropic drugs and neonatal effects 
In studies II, III and IV, we aimed at further describing neonatal adaptation 
difficulties in infants prenatally exposed to antidepressants or mood stabi-
lizing drugs. Study II showed that a majority of all infants born to mothers 
with SSRI or SNRI treatment during pregnancy are healthy in the neona-
tal period. Seventy one percent received the diagnostic code ‘healthy infant’ 
in the discharge examination from the maternal ward. Only 3 % developed 
a severe abstinence syndrome and 22 % had signs of mild abstinence, the 
symptoms mainly arising from the CNS. Other studies have shown slightly 
higher prevalence of PNAS in infants with intrauterine SSRI/SNRI exposure 
(163, 167). The relatively low prevalence of PNAS and low admittance rate 
to NCU (13 %) in this study might be due to our exclusion of women using 
other neurotropic medications and women with substance abuse. In study III 
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we were able to compare infants exposed to antidepressants with unexposed 
infants in a large, population-based cohort. This comparison has been done 
previously in Swedish, register-based studies (90, 168) but never before with 
the additional information that the neonatal quality register SNQ and PRS 
can provide. MBR does not include data on NCU admission, length of stay 
and duration of CPAP treatment. We also increased the precision in the as-
sessment of exposure by using the PDR (169). 
We observed an increased risk of admission to NCU in all groups exposed 
to antidepressant drugs, with the highest proportion of neonatal care after 
exposure to SNRI or TCA in late pregnancy, 25 and 27 %, respectively. Since 
the median duration of NCU stay for the exposed infants was almost one 
week, we believe that they were admitted due to substantial neonatal pro-
blems and not only as a precaution. CPAP treatment was more common in 
exposed infants than in the non-exposed and the duration of treatment was 
the same in both groups. The higher risk of admittance to NCU in exposed vs 
non-exposed infants remained largely unchanged after adjustment for GA and 
intrauterine growth, indicating that the association between exposure to anti-
depressants and neonatal morbidity is not primarily mediated via preterm 
birth or intrauterine growth restriction. In fact, the ORs were in most cases 
more pronounced when restricting the analysis to full-term infants only. Ho-
wever, study III as well as other studies have described an association bet-
ween antidepressants during pregnancy and prematurity (90, 97). That means 
that the negative influence of the prenatal drug exposure on neonatal morbi-
dity can be mediated both through preterm birth, which is highly associated 
to all neonatal morbidity, and the drug effect itself which is more pronounced 
in full-term infants. 
Untreated depression and anxiety disorders have, just like antidepressant 
agents, in some studies been linked to adverse neonatal outcomes such as 
neonatal adaptation difficulties, preterm birth and lower Apgar scores (44, 53, 
170-172). The analysis of late vs early exposure was an attempt to account for 
the underlying psychiatric condition. The increased odds of neonatal care af-
ter antidepressant use in late pregnancy suggest a true association with phar-
macotherapy. Today, there seem to be consensus that antidepressants in fact 
are causing PNAS (98, 167, 173), but how much of this condition that can be 
attributed to the underlying maternal depression or anxiety disorder might be 
difficult to establish until a study with randomization is performed. Preclini-
cal data such as animal studies on several species (66) and studies on human 
embryos and placentas describe several effects after exposure to SSRI and 
maternal depression, including modifications of gene expression in placentas 
of depressed women with SSRI treatment and altered embryo development 
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and protein expression in embryos exposed to fluoxetine (174, 175). These 
findings are of course very valuable, but epidemiological and clinical studies, 
such as the ones included in this thesis, are also needed in order to develop 
clinical guidelines. 
The rate of neonatal hypoglycemia was surprisingly high in study II, 19 %. 
In study III, the incidence of hypoglycemia among infants exposed to SSRI 
was only 4 %, compared to 2.4 % in non-exposed, OR 1.3 (95 % CI 1.2-
1.4), no vs any SSRI use, adjusted for maternal factors and neurotropic drugs. 
The discrepancy in absolute risks is due to differences in data collection in a 
study based on clinical records and a register-based study. In study II, neo-
natal charts from the maternity and/or neonatal ward were scrutinized and 
all infants with recorded blood glucose < 2.6 mmol/L were considered hypo-
glycemic. In study III, ‘hypoglycemia’ meant having the diagnostic code for 
hypoglycemia registered in SNQ and/or MBR, or checkbox checked in SNQ. 
We thereby conclude that the incidence of hypoglycemia may be underesti-
mated in register-based studies. Other studies have also found an association 
between prenatal antidepressant exposure and hypoglycemia (176). However, 
hypoglycemia is fairly common in all infants, e.g. one study reported hypo-
glycemia in 12 % of full-term and 14 % of preterm infants (177). In obser-
vational studies such as study II and III, increased risk of hypoglycemia may 
also be due to detection bias. Jitteriness and tremor, caused by SSRI exposure, 
can be perceived as symptoms of hypoglycemia leading to the measurement 
of blood glucose, increasing the chance of detecting a low value. Hypogly-
cemia in infants is however a potentially serious condition (178, 179) and 
clinicians should be aware of the association and evaluate infants exposed to 
antidepressants accordingly.
In study II, we investigated neonatal symptoms in infants exposed to anti-
depressants during the last part of the pregnancy using health care records 
including information on NAS. Time to peak value of NAS was analyzed 
but failed to show any significant differences between the groups. Individual 
factors such as metabolic and transporter capacity of SSRI/SNRI in mother 
and child may be of greater influence than drug class in determining strength 
and duration of symptoms (105, 180, 181), but we cannot rule out that a larger 
group size and/or prospective data collection with more stringent evaluation 
of NAS would have given other results. Time to peak score varied between 2 
and 90 hours. Our results therefore support the notion that PNAS occurs early 
and is usually of relatively short duration (163). However, if duration of stay 
at the maternal ward is very short, symptoms may arise after the family has 
left the hospital. 
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MMD and neurotropic medication during pregnancy are often described as 
important risk factors for adverse events in the neonatal period (16, 18, 176, 
182, 183). In study IV we saw a relatively low incidence of neonatal morbi-
dity, 20/27 infants exposed to MMD, where neonatal data was available, had 
a normal neonatal period. Three out of eight infants in the group with MMD 
but not exposed to lithium were admitted to NCU, all due to prematurity. One 
pair of twins, which is a major risk factor for prematurity, was included in 
this group. In previous studies, prematurity has been associated to maternal 
BD (129, 131). Our study found no cases of neonatal hypothyroidism after 
lithium exposure in utero but due to our small sample size we still advice 
measurement of thyroid hormones in the neonatal period in lithium-exposed 
infants. A correlation between maternal lithium concentrations and neonatal 
outcome has previously been described (16). The low neonatal morbidity in 
this cohort may partly be due to adequate therapeutic drug monitoring during 
pregnancy but also due to low incidence of maternal smoking and, for the 
most part, stable socio-economic conditions in the cohort. 
Previous studies have described increased relative risks of PPHN after intra-
uterine exposure to SSRI, but with low absolute risks (109, 110, 141, 184). 
In study III, we were able to confirm this association, primarily in full-term 
infants where the adjusted (maternal factors and use of neurotropic drugs) OR 
was 2.6 (95 % CI 1.4-4.8). We conclude that PPHN and SSRI exposure in late 
pregnancy are associated, most likely with a causal relationship. The absolute 
risks are however small, with NNH around 300. Obviously, awareness of this 
association may be beneficial to the SSRI-exposed infant in respiratory dist-
ress. On the other hand, from a research perspective, the incidence of PPHN 
may rise with increasing awareness of the condition in this patient group, due 
to the fact that early echocardiograms may detect milder cases of PPHN that 
otherwise might have been diagnosed as other types of respiratory or circula-
tory illnesses. This type of detection bias has been suggested regarding cardi-
ac malformations in paroxetine-exposed infants (92). However, the mortality, 
need for ventilator treatment and duration of NCU care did not significantly 
differ between exposed and non-exposed infants with PPHN after adjustment 
for GA meaning that we did not detect milder cases in our cohort.
Caregivers that meet infants prenatally exposed to antidepressants or mood 
stabilizers need to be aware of symptoms that may arise and evaluate ac-
cordingly. The parents have a right to receive balanced information regar-
ding these risks in order to be prepared for the fact that the infant may need 
prolonged observation after birth, either at a NCU or, in the vast majority of 
cases, in the maternity ward. NAS is sometimes used, however not validated 
in SSRI-exposed neonates (163) . Other methods of evaluation have been 
suggested (105).
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To prevent neonatal morbidity in children born to mothers with psychiatric 
illnesses it may be more relevant to address maternal health from several ang-
les rather than focus on neurotropic medication alone. We saw a higher inci-
dence of cigarette smoking and obesity in mothers with antidepressant treat-
ment in study III and these factors were included in the ‘maternal factors’ that 
we adjusted for. Among women with antidepressants and other neurotropic 
medications during pregnancy, the incidence of smoking and obesity (BMI 
>30 kg/m2) were each around 20 %. Maternal obesity and smoking are asso-
ciated to considerable child morbidity (185-189). Substantial efforts are made 
by maternity care units to inform mothers-to-be on the benefits of weight 
control and smoking cessation but there may be substantial health benefits for 
their future children (and, of course, the mothers themselves) if psychiatric or 
primary care health care providers also direct similar efforts towards women 
of childbearing potential, prior to pregnancy (190). And again, maternal psy-
chiatric symptoms may have negative implications for the infant. Inadequa-
tely treated maternal depression during pregnancy increases the risk of PPD 
which can have negative effects on the newborn infant, including insecure 
mother-infant attachment (39, 56).
5.3  Discussion on neurotropic drugs and long-term outcome 
In study IV we aimed at expanding our understanding of the long-term out-
come of children born to mothers with BD or other severe mood disorders 
and exposure to mood stabilizing drugs during pregnancy, an area where in-
formation so far has been limited (132, 134, 135). Since lithium readily pas-
ses the placenta, has affinity for the CNS and is known to cause (resolving) 
neurotoxicity to the newborn infant (16, 191), there was enough biological 
plausibility that the immature brain could be affected by prenatal exposure to 
lithium in order to perform this study. On the other hand, preclinical data sug-
gest a neuroprotective effect from lithium in the immature brain (192-194). 
With the exception of PSQ results, we observed surprisingly high IQ scores 
for both the control group and the MMD exposed children, particularly in the 
lithium-exposed group. This can be interpreted as a result of the high propor-
tion of well educated women in the cohort and we can speculate that there 
was a participation bias towards women with high education and stable social 
conditions, especially in the control group. The fact that we did not have the 
possibility to test the mothers’ IQ is a limitation of the study. The results for 
PSQ differed between both groups of children exposed to MMD and ‘con-
trols’ after Tobit model analyses. The former groups also had PSQ results 
significantly below 100. PSQ results are difficult to interpret in children of 
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this age group. Processing speed is important with regard to working memory 
(195) but at this point, with a small sample size, missing data and a young 
cohort our interpretation of the results must be very cautious. 
Our results in study I show an association between exposure to two or more 
AED during pregnancy and a significantly increased risk of not receiving a 
LC from compulsory school at age 16. No LC usually means that the child 
was not attending general school due to intellectual disability and the results 
suggest that exposure to polytherapy during fetal life may have negative ef-
fects on long-term neurodevelopment. These results are in accordance with 
previous clinical and preclinical studies that have demonstrated a negative 
effect on the development of the immature fetal brain exposed to several AED 
simultaneously in utero (196-198). There was also a tendency in all children 
born to WWE towards a decreased probability to receive high grades in Mat-
hematics, Swedish, English and Sports, particularly in children exposed to 
CBZ. These results are more difficult to interpret, since a decreased chance 
of getting a high grade can be attributed to a multitude of factors. Residual 
confounding cannot be excluded. Most previous studies report that CBZ does 
not seem to have a negative effect on neurodevelopment but evidence is not 
entirely conclusive (22, 76, 81, 199). 
Several methodological considerations are important in the assessment of 
neurodevelopment in children prenatally exposed to neurotropic drugs: 1) 
Controlling for important confounders, such as socioeconomic factors, pa-
rental IQ, parental health during and after pregnancy and factors related to 
the child, for example GA. 2) Follow up at an adequate age. The evaluation 
should be performed at an age where more subtle difficulties are detectable. 
3) Standardized and quantifiable methods to assess child development and 
behavior are preferred over for example parental recall of developmental mi-
lestones and other subjective and crude measurements. The assessor should 
be blinded to exposure. In two of the included studies, I and IV, we investiga-
ted long-term neurodevelopment in children prenatally exposed to AED and 
mood stabilizing drugs, respectively. The methods used were different but 
provide examples on how the above mentioned methodological challenges 
can be addressed. 
In study I, we used population-based registers which provided us with a large 
enough cohort and a long time to follow-up (16 years of age). However, regis-
ters are sometimes limited regarding the information they provide. We had in-
formation on maternal level of education but no other socio-economic factors 
and no information on parental IQ, which is an important determinant for in-
telligence (200). We also lacked data on severity of maternal illness and since 
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polytherapy in the mother can be associated to a more severe form of epilepsy 
and decreased maternal health, confounding by indication in children of wo-
men with polytherapy treatment cannot be ruled out. The main outcome we 
investigated, LC, is a fairly crude outcome that only tells us whether the child 
had a grade in any subject. The absence or presence of a LC does not reveal 
mild neurodevelopmental difficulties but has the advantage of describing an 
important functional outcome rather than test results.
In study IV, information on maternal health, social situation and drug treat-
ment during and after pregnancy was available, obtained from the clinical 
register kept at the Affective Disorder Outpatient Clinic and from the mater-
nal interview at the research visit. We were however limited by a fairly small 
sample size. The children were tested at age four to five which is an age where 
severe neurodevelopmental disturbances can be detected but milder difficul-
ties may be hard to diagnose. Another methodological limitation of study IV 
was that children who did not perform well enough on the different subsca-
les of WPPSI-III did not receive an IQ result for these subtests, resulting in 
non-ignorable missing data. A Tobit regression model was used to account 
for missing data and avoid overestimation of mean scores. Also, several of 
the women in the study had a large number of other neurotropic medications 
during pregnancy, making the interpretation of the results more difficult. This 
is however often the case in observational studies.
In Sweden and the other Scandinavian countries there are excellent opportu-
nities to perform nation-wide epidemiological studies using the population-
based health registers. But register studies can only provide us with some 
parts of the puzzle that this important and rapidly expanding research field 
entail. Animal studies and clinical cohort studies are other important contri-
butions. But regardless of type of study, the most important thing is that the 
data are interpreted wisely. Cooperation between different parts of the medi-
cal field, for example psychiatry, pediatrics, pharmacology and obstetrics, is 
often crucial to plan and perform relevant and precise studies.
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6.  CONCLUSIONS
• Epilepsy, bipolar disorders, depression and anxiety disorders are com-
mon disorders among women of childbearing age. Pharmacotherapy 
is often necessary to ensure symptom control and good health, also 
during pregnancy. 
• In study I, we conclude that prenatal exposure to several AED in utero 
is associated to a decreased chance of receiving a final grade from 
compulsory school. This suggests that polytherapy may have negative 
effects on neurodevelopment and should, if possible with maintained 
seizure control, be avoided in pregnant women. 
• Study III, a large, population-based register study, demonstrated that 
infants born to mothers using SSRI and other antidepressants during 
pregnancy have a moderately increased risk of admittance to neonatal 
care. OR for neonatal care after use of antidepressants in late vs early 
pregnancy was 1.7 (95 % CI 1.6-1.9, adjusted estimate). SSRI during 
pregnancy was associated to increased risk of neonatal respiratory di-
sorders, hypoglycemia and PPHN. The severity of the illness did not 
differ in SSRI-exposed and non-exposed infants with PPHN, after ad-
justment for gestational age. 
• In study II, 205 infants born to mothers with use of SSRI/SNRI during 
late pregnancy were assessed with NAS/Finnegan score. Seventy four 
percent of these infants had no signs of neonatal abstinence/maladap-
tation symptoms. No significant differences were observed regarding 
the level of abstinence between the different antidepressant exposure 
groups. 
• Study IV describe no significant association between prenatal expo-
sure to lithium or maternal mood disorder and performance IQ, verbal 
IQ and full scale IQ at preschool age. None of the twenty infants ex-
posed to lithium in utero developed neonatal thyroid disorder. 
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7.  FUTURE PERSPECTIVES
Our studies show a need for further studies within this field of research. A 
larger clinical evaluation of children born to mothers with bipolar disorders 
and mood stabilizing drugs during pregnancy would be valuable, including 
psychological tests and parental interview. Since BD and co-morbid condi-
tions such as ADHD may be passed on to the next generation, an evaluation 
of the children at school age or even beyond that, would be interesting. Col-
laboration between researchers in several domains, such as psychiatry, clini-
cal pharmacology, psychology, obstetrics, pediatrics and child and adolescent 
psychiatry is necessary to ensure high quality in this type of study. Multicen-
ter design is preferable to ensure adequate power. 
Population-based registers are excellent data sources for epidemiological stu-
dies. To combine national databases such as MBR, PDR and NPR with a na-
tional quality register, similar to what we did in study III, might be of further 
interest. There is a national quality register on BD, BipoläR, which could be 
useful in answering questions about pregnancy and BD. Several questions 
on lithium and breastfeeding remain unanswered and this is also a potential 
research field. The neuroprotective effects of lithium that have been reported 
in animal studies have not yet been studied in humans and might be of great 
interest in other pediatric research areas.
A repeated study on school results and prenatal exposure to AED may also be 
interesting since many new drugs have been introduced since the time period 
during which the children in study I were born and the long-term effects of 
these drugs are not yet fully described. Adding data from the PDR would also 
contribute substantially to the study design. However, since PDR was intro-
duced in 2005, it is not yet possible to perform an evaluation of final grades 
in compulsory school. Further, more detailed studies that relate maternal drug 
concentration measurements and cognition in children prenatally exposed to 
certain AED would be of value.
Another important area of research, bordering to the studies included in this 
thesis, is the understanding of how all the existing information on chronic 
illness, drugs and pregnancy is being used. Risk perceptions- how do women 
and health care providers perceive risks related to neurotropic medication 
and untreated maternal illness? Studies continue to be published in this field 
of research but how is this research used in clinical practice, and what are the 
effects?
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8.  POPULÄRVETENSKAPLIG SAMMANFATTNING
Sjukdomar som epilepsi, bipolär sjukdom samt depression- och ångesttill-
stånd leder till stort lidande och kan vara livshotande, även för kvinnor som 
är gravida. Att effektivt behandla dessa sjukdomar är givetvis viktigt. Obe-
handlade symptom, som t ex kramper eller djup depression kan ha allvarliga 
konsekvenser även för den gravida kvinnans ofödda barn. Dock kan läkeme-
delsbehandling under graviditet vara förenat med risker för fostret. Denna 
avhandling fokuserar på att beskriva hälsa i nyföddhetsperioden och hjärnans 
utveckling hos barn som under graviditeten exponerats för antidepressiva lä-
kemedel, stämningsstabiliserande läkemedel som används vid bipolär sjuk-
dom eller läkemedel mot epilepsi. 
I studie I har vi använt nationella register som baseras på hela befolkningen 
för att undersöka slutbetyg i nionde klass hos barn till kvinnor med epilepsi 
som under graviteten behandlats med epilepsiläkemedel. Barn till kvinnor 
som behandlats med två eller fler läkemedel under graviditeten hade en ökad 
risk att inte få något slutbetyg från grundskolan. I de flesta fall betyder av-
saknad av skolbetyg att man inte kunnat gå i vanlig grundskola på grund av 
inlärningssvårigheter. Barn som hade exponerats för en sorts antiepileptika 
hade inte signifikant ökad risk för att bli utan slutbetyg.
Exponering för depressionsläkemedlen SSRI (selektiva serotoninåterupp-
tagshämmare) eller SNRI (serotonin- och noradrenalinåterupptagshämmare) 
i sen graviditet kan leda till utsättningssymtom (”abstinens”) hos det nyfödda 
barnet. Studie II beskriver barn födda till mödrar som behandlats med anti-
depressiva läkemedel under sista delen av graviditeten. Milda utsättnings-
symtom sågs hos 22 % medan endast 3 % hade svåra utsättningssymtom. Det 
fanns ingen signifikant skillnad mellan olika sorters antidepressiva läkemedel 
avseende grad av utsättningssymtom. Knappt en femtedel av barnen hade lågt 
blodsocker.
I studie III undersöktes hälsa i nyföddhetsperioden hos barn som exponerats 
för antidepressiva i en större, registerbaserad undersökning. Vi studerade to-
talt 741 040 barn, varav 22 507 (3 %) hade exponerats för antidepressiva, 
framförallt SSRI, under graviditeten. Barn som exponerats för antidepressiva 
hade en måttligt ökad risk för inläggning på neonatalavdelning jämfört med 
icke exponerade barn, oddskvot 1,5 (95 % konfidensintervall 1,4-1,6). SSRI-
exponerade barn hade måttligt ökad risk för andningsstörningar, symtom från 
centrala nervsystemet och lågt blodsocker.
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Få studier har undersökt hur barn till kvinnor med bipolär sjukdom utvecklas. 
I studie IV undersöktes 28 barn till kvinnor med affektiv sjukdom (merparten 
hade bipolär sjukdom I eller II) samt 11 barn där mamman inte haft någon 
psykisk ohälsa under graviditeten. Vi fann inga statistiskt signifikanta skillna-
der gällande barnens IQ vid 4-5 års ålder. Resultaten för snabbhetsindex, en 
del av begåvningsundersökningen, var lägre hos barn till mödrar med affektiv 
sjukdom- med eller utan exponering för läkemedlet litium i fosterlivet- men 
dessa resultat är svårtolkade hos så små barn.  
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